The University of Chicago Header Logo

Connection

Steven Chmura to Humans

Back to Details
This is a "connection" page, showing publications Steven Chmura has written about Humans.
Steven Chmura
Connection Strength
0.898
Humans
  1. Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):840-842.
    View in: PubMed
    Score: 0.025
  2. From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):576-580.
    View in: PubMed
    Score: 0.025
  3. Oligometastatic Breast Cancer. Semin Radiat Oncol. 2022 07; 32(3):282-290.
    View in: PubMed
    Score: 0.024
  4. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.023
  5. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 01; 7(6):845-852.
    View in: PubMed
    Score: 0.023
  6. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med. 2021 May; 10(5):6028-6044.
    View in: PubMed
    Score: 0.022
  7. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.022
  8. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.021
  9. The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. Hematol Oncol Clin North Am. 2020 02; 34(1):307-320.
    View in: PubMed
    Score: 0.020
  10. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? Cancer. 2018 07 15; 124(14):2878-2880.
    View in: PubMed
    Score: 0.019
  11. Reply to S.C. Formenti et al. J Clin Oncol. 2018 09 01; 36(25):2662-2663.
    View in: PubMed
    Score: 0.018
  12. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.018
  13. PMRT: Please Mind Randomized Trials. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):976-977.
    View in: PubMed
    Score: 0.017
  14. Oligometastasis-Directed Ablative Therapy: A Clinical Trial Question. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):448.
    View in: PubMed
    Score: 0.017
  15. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.016
  16. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
    View in: PubMed
    Score: 0.016
  17. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book. 2015; e8-15.
    View in: PubMed
    Score: 0.015
  18. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol. 2014 Dec; 41(6):790-7.
    View in: PubMed
    Score: 0.014
  19. Treatment of brain metastases. Oncology. 2014; 87(6):321-9.
    View in: PubMed
    Score: 0.014
  20. Hypofractionated radiotherapy does not increase acute toxicity in large-breasted women: results from a prospectively collected series. Am J Clin Oncol. 2014 Aug; 37(4):322-6.
    View in: PubMed
    Score: 0.014
  21. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.014
  22. Radiation oncology medical student clerkship: implementation and evaluation of a bi-institutional pilot curriculum. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):45-50.
    View in: PubMed
    Score: 0.014
  23. A prospective study of the utility of magnetic resonance imaging in determining candidacy for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):615-22.
    View in: PubMed
    Score: 0.012
  24. Feasibility and acute toxicity of hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):79-83.
    View in: PubMed
    Score: 0.012
  25. Predictors of competing mortality in early breast cancer. Cancer. 2010 Dec 01; 116(23):5365-73.
    View in: PubMed
    Score: 0.011
  26. Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
    View in: PubMed
    Score: 0.011
  27. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009 Nov; 93(2):298-301.
    View in: PubMed
    Score: 0.010
  28. Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation. Cancer. 2008 Nov 01; 113(9):2408-14.
    View in: PubMed
    Score: 0.010
  29. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7.
    View in: PubMed
    Score: 0.009
  30. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007 Oct 10; 25(29):4581-6.
    View in: PubMed
    Score: 0.009
  31. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol. 2007 Sep 10; 25(26):4090-5.
    View in: PubMed
    Score: 0.009
  32. Evolving use of radiotherapy and radiosurgery in the treatment of pituitary adenomas. Expert Rev Anticancer Ther. 2006 Sep; 6 Suppl 9:S93-8.
    View in: PubMed
    Score: 0.008
  33. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005 Oct 01; 63(2):354-61.
    View in: PubMed
    Score: 0.008
  34. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Jul; 643(8072):810-819.
    View in: PubMed
    Score: 0.007
  35. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Dec 02; 134(23).
    View in: PubMed
    Score: 0.007
  36. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol. 2004 Dec; 31(6):816-21.
    View in: PubMed
    Score: 0.007
  37. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.007
  38. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
    View in: PubMed
    Score: 0.007
  39. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.007
  40. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
    View in: PubMed
    Score: 0.007
  41. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.007
  42. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst. 2023 11 08; 115(11):1278-1293.
    View in: PubMed
    Score: 0.007
  43. De Novo Oligometastatic Breast Cancer. J Clin Oncol. 2023 12 01; 41(34):5237-5241.
    View in: PubMed
    Score: 0.007
  44. Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
    View in: PubMed
    Score: 0.007
  45. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.007
  46. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
    View in: PubMed
    Score: 0.007
  47. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. JAMA Netw Open. 2023 04 03; 6(4):e2310117.
    View in: PubMed
    Score: 0.006
  48. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.006
  49. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It? Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):561-570.
    View in: PubMed
    Score: 0.006
  50. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.006
  51. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
    View in: PubMed
    Score: 0.006
  52. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. J Neurooncol. 2021 Dec; 155(3):297-306.
    View in: PubMed
    Score: 0.006
  53. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.006
  54. Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
    View in: PubMed
    Score: 0.006
  55. Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol. 2022 Jan-Feb; 12(1):68-77.
    View in: PubMed
    Score: 0.006
  56. Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption. JAMA Dermatol. 2021 08 01; 157(8):998-1000.
    View in: PubMed
    Score: 0.006
  57. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.006
  58. Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS). J Appl Clin Med Phys. 2021 Mar; 22(3):196-206.
    View in: PubMed
    Score: 0.006
  59. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.006
  60. A study of the dosimetric impact of daily setup variations measured with cone-beam CT on three-dimensional conformal radiotherapy for early-stage breast cancer delivered in the prone position. J Appl Clin Med Phys. 2020 Dec; 21(12):146-154.
    View in: PubMed
    Score: 0.005
  61. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.005
  62. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. J Thorac Oncol. 2020 07; 15(7):1137-1146.
    View in: PubMed
    Score: 0.005
  63. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
    View in: PubMed
    Score: 0.005
  64. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020 04 01; 38(10):1019-1029.
    View in: PubMed
    Score: 0.005
  65. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
    View in: PubMed
    Score: 0.005
  66. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.005
  67. Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation. Pract Radiat Oncol. 2019 Nov; 9(6):492-495.
    View in: PubMed
    Score: 0.005
  68. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
    View in: PubMed
    Score: 0.005
  69. National Radiation Oncology Medical Student Clerkship Trends From 2013 to 2018. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):24-26.
    View in: PubMed
    Score: 0.005
  70. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma. Neurologist. 2018 Sep; 23(5):163-166.
    View in: PubMed
    Score: 0.005
  71. Structured Radiation Oncology Clerkship Curricula: Evaluating the Effect on Residency Applicant Knowledge of Radiation Oncology. J Am Coll Radiol. 2018 Sep; 15(9):1330-1334.
    View in: PubMed
    Score: 0.005
  72. Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys. 2018 Jul; 19(4):205-213.
    View in: PubMed
    Score: 0.005
  73. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626.
    View in: PubMed
    Score: 0.005
  74. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.005
  75. American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):1057-1066.
    View in: PubMed
    Score: 0.004
  76. Towards frameless maskless SRS through real-time 6DoF robotic motion compensation. Phys Med Biol. 2017 Nov 13; 62(23):9054-9066.
    View in: PubMed
    Score: 0.004
  77. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol. 2017 Aug; 40(4):418-422.
    View in: PubMed
    Score: 0.004
  78. Management of glioblastoma in elderly patients. J Neurol Sci. 2017 Sep 15; 380:250-255.
    View in: PubMed
    Score: 0.004
  79. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat. 2017 04; 162(2):317-328.
    View in: PubMed
    Score: 0.004
  80. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
    View in: PubMed
    Score: 0.004
  81. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):161-166.
    View in: PubMed
    Score: 0.004
  82. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. Int J Radiat Oncol Biol Phys. 2017 01 01; 97(1):155-163.
    View in: PubMed
    Score: 0.004
  83. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e291-e298.
    View in: PubMed
    Score: 0.004
  84. Taking "the Game" Out of The Match: A Simple Proposal. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):945-8.
    View in: PubMed
    Score: 0.004
  85. The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Expert Rev Anticancer Ther. 2015; 15(12):1459-71.
    View in: PubMed
    Score: 0.004
  86. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan; 126(2):309-16.
    View in: PubMed
    Score: 0.004
  87. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):217-9.
    View in: PubMed
    Score: 0.004
  88. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med. 2015 Apr; 4(4):513-8.
    View in: PubMed
    Score: 0.004
  89. An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):58-64.
    View in: PubMed
    Score: 0.004
  90. Assessment of interfractional variation of the breast surface following conventional patient positioning for whole-breast radiotherapy. J Appl Clin Med Phys. 2014 Sep 08; 15(5):4921.
    View in: PubMed
    Score: 0.004
  91. Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys. 2014 Mar 06; 15(2):4547.
    View in: PubMed
    Score: 0.003
  92. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
    View in: PubMed
    Score: 0.003
  93. A national radiation oncology medical student clerkship survey: didactic curricular components increase confidence in clinical competency. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):51-6.
    View in: PubMed
    Score: 0.003
  94. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
    View in: PubMed
    Score: 0.003
  95. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.003
  96. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
    View in: PubMed
    Score: 0.003
  97. Radiation oncology fourth-year medical student clerkships: a targeted needs assessment. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):296-7.
    View in: PubMed
    Score: 0.003
  98. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.003
  99. Ocular melanoma metastasis to the cervical spine. J Clin Neurosci. 2012 Apr; 19(4):610-1.
    View in: PubMed
    Score: 0.003
  100. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650.
    View in: PubMed
    Score: 0.003
  101. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.003
  102. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
    View in: PubMed
    Score: 0.003
  103. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011 Apr; 38(2):243-53.
    View in: PubMed
    Score: 0.003
  104. AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging. Mol Imaging Biol. 2010 Oct; 12(5):463-7.
    View in: PubMed
    Score: 0.003
  105. A novel functional CT contrast agent for molecular imaging of cancer. Phys Med Biol. 2010 Aug 07; 55(15):4389-97.
    View in: PubMed
    Score: 0.003
  106. Rationally simplified bistramide analog reversibly targets actin polymerization and inhibits cancer progression in vitro and in vivo. J Am Chem Soc. 2010 Jun 02; 132(21):7288-90.
    View in: PubMed
    Score: 0.003
  107. Validation of temporal optimization effects for a single fraction of radiation in vitro. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):1240-6.
    View in: PubMed
    Score: 0.003
  108. Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions. Med Dosim. 2009; 34(2):126-32.
    View in: PubMed
    Score: 0.002
  109. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.002
  110. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol. 2006 Jun; 79(942):497-503.
    View in: PubMed
    Score: 0.002
  111. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.002
  112. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
    View in: PubMed
    Score: 0.002
  113. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
    View in: PubMed
    Score: 0.002
  114. Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance? Cancer. 2005 Feb 15; 103(4):664-71.
    View in: PubMed
    Score: 0.002
  115. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):445-53.
    View in: PubMed
    Score: 0.002
  116. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev. 2003 Feb; 29(1):21-30.
    View in: PubMed
    Score: 0.002
  117. In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology. 1999 Sep; 54(3):573-7.
    View in: PubMed
    Score: 0.001
  118. Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res. 1998 Oct; 4(10):2391-8.
    View in: PubMed
    Score: 0.001
  119. Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
    View in: PubMed
    Score: 0.001
  120. Human APC gene expression in rodent colonic epithelium in vivo using liposomal gene delivery. Hum Mol Genet. 1994 Nov; 3(11):2005-10.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.